SBIR/STTR Research Award

An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts

Award identifier b73d50de768eabaf0d6a7356e0185b0d670b1764a36ffe2ea7e9d23476b0b1a6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$346,755

Program and phase

SBIR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
REVEL PHARMACEUTICALS INC.
Proposal award date
2024-07-01
Contract end date
2025-06-30
UEI
RBFMLGKG8KZ3
Solicitation number
PA23-230
Topic code
300

Research abstract

PROJECT SUMMARY Advanced glycation endproducts (AGEs) are hallmarks of mammalian aging and disease. Nε-carboxyethyl-lysine (CEL) in particular, is among the most abundant AGEs accumulating in tissue proteins with aging, and is an important marker of glycation, oxidative stress, and disease. Current techniques for reliable measurement of CEL are slow, expensive (>$120/sample), and not readily available to many academic research labs nor easily applied for routine analysis of clinical samples. Development of a convenient method for measurement of CEL would democratize the research tools used to study AGEs and advance the tools available to study and treat diseases at the interface of aging, glycation and oxidative stres. Revel has discovered a CEL oxidase enzyme which oxidizes CEL to lysine. The newly discovered CEL oxidase provides an opportunity to develop enzymes for diagnostic use in monitoring CEL-modifications. The goal of this Phase I SBIR is to develop a rapid, one-pot, inexpensive enzymatic test (<$10/sample) to measure CEL. The proposed assay will be developed analogous to the enzymatic HbA1c test which is used to assess patient blood sugar levels and diagnose diabetes. In Phase II, we will develop a workflow for CEL detection in patient samples. Eventually, further engineering of the enzyme for removal of CEL from endogenous proteins could yield a ground-breaking tool for reversing glycoxidatively damaged proteins in clinical medicine.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $2,942,757. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.